Chemotherapy or combined modality treatment: The optimal treatment for Hodgkin's Disease

Journal of Clinical Oncology

Volumn 22, Issue 1, 2004, Pages 15-18

  Diehl, Volker ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; EDITORIAL; HODGKIN DISEASE; HUMAN; LUNG TOXICITY; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; SEPSIS; SOLID TUMOR; TESTIS TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HODGKIN DISEASE; HUMANS; PATIENT CARE PLANNING; PROGNOSIS; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS;

EID: 21044438843     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.10.910     Document Type: Editorial

References (25)

1. Van Leeuwen FE, Klokman WJ, van't Veer MB, et al: Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence of young adulthood. J Clin Oncol 18:487, 2000
2. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al: Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 21:3431-3439, 2003
3. De Vita VT Jr: Hodgkin's disease: Clinical trials and travails. N Engl J Med 348:2375-2376, 2003
4. Longo DL: Radiation therapy in the treatment of Hodgkin's disease: Do you see what I see? J Natl Cancer Inst 95:928-929, 2003
5. Yahalom J: Breast cancer after Hodgkin disease: Hope for a safer cure. JAMA 290:529-533, 2003
6. Hancock SL, Tucker MA, Hoppe RT: Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 270:1949, 1993
7. Ng AK, Bernardo MP, Weller E, et al: Long-term survival and competing causes of death in patients with early-stage Hodkgin's disease treated at age 50 or younger. J Clin Oncol 20:2101-2108, 2002
8. Canellos GP, Niedzwiecki D: Long-term follow-up of Hodgkin's disease trial. N Engl J Med 346:1417-1418, 2002
9. Diehl V, Franklin J, Pfreundschuh M, et al: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348:2386-2395, 2003
10. Aleman BM, Raemaekers JM, Tirelli U, et al: European Organization for Research and Treatment of Cancer Lymphoma Group: Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 348:2396-2406, 2003
11. Chisesi T, Federico M, Levis A, et al: Intergruppo Italiano Linfomi: ABVD versus Stanford V versus MEC in unfavourable Hodgkin's lymphoma: Results of a randomised trial. Ann Oncol 13:102-106, 2002 (suppl 1)
12. Raemaekers J, Kluin-Nelemans H, Teodorovic I, et al: The achievements of the EORTC Lymphoma Group: European Organisation for Research and Treatment of Cancer. Eur J Cancer 38:5107-113, 2002 (suppl 4)
13. Diehl V, Schiller P, Engert A, et al: Results of the Third Interim Analysis of the HD12 Trial of the GHSG: 8 courses of BEACOPP with or without additive radiotherapy for advanced stage Hodgkin's lymphoma. Blood 102:85, 2003 (suppl 1)
14. Weiner M, Leventhal B, Brecher M, et al: Randomized study of intensive MOPP-ABVD with or without low dose total nodal radiation therapy in the treatment of stage IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: A Pediatiric Oncology Group study. J Clin Oncol 15:2769-2779, 1997
15. Nachman JB, Sposto R, Herzog P, et al: Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 20:3765-3771, 2002
16. Fabian CJ, Mansfield CM, Dahlberg S, et al: Low dose involved field radiation after chemotherapy in advanced Hodgkin's disease. Ann Intern Med 120:903-912, 1994
17. Laskar S, Gupta T, Vimal S, et al: Consolidation radiation after complete remission in Hodgkin's disease following six cycles of ABVD chemotherapy: Is there a need? J Clin Oncol 22:62-68, 2004
18. Nachman J: In reply. J Clin Oncol 21:1192, 2003
19. Franklin J, Schellong G, Diehl V: Is age a risk factor for the treatment of Hodgkin's disease in children and young adults? Comparative analysis of data from the German trials. J Cancer Res Clin Oncol 124:1998 (suppl)
20. Diehl V, Pfreundschuh M, Loeffler M, et al: Chemotherapy of Hodgkin's lymphoma with alternating cycles of COPP (cyclophosphamide, vincristin, procarbazine, prednisone) and ABVD (doxorubicin, bleomycin, vinblastin, and dacarbazine): Results of the HD1 and HD3 trials of the German Hodgkin Study Group. Med Oncol Tumor Pharmacother 6:155-162, 1989
21. Loeffler M, Brosteanu O, Hasenclever D, et al: Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease: International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol 16:818-829, 1998
22. Noordijk E, Carde P, Hagenbeek A: Combination of radiotherapy and chemotherapy is advisable in all patients with clinical stage I-II Hodgkin's disease: Six-year results of the EORTC-GPMC controlled clinical trials "H7-VF", "H7-F" and "H7-U." Int J Radiat Oncol Biol Phys 39:173, 1997
23. Hancock BW, Gregory WM, Cullen MH, et al: British National Lymphoma Investigation, Central Lymphoma Group: ChIVPP alternating with PABIOE is superior to PABIOE alone in the initial treatment of advanced Hodgkin's disease-Results of a British National Lymphoma Investigation/ Central Lymphoma Group randomised controlled trial. Br J Cancer 84:1293-1300, 2001
24. Raemaekers J, Burgers M, Henry-Amar M, et al: Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: Interim results from the ongoing EORTC-LCG and GPMC phase III trial. Ann Oncol 8:111-114, 1997 (suppl 1)
25. Diehl V, Stein H, Connors JM: Hodgkin's lymphoma: Biology and treatment strategies from primary, refractory, and relapsed disease, American Society of Hematology, Education Program Book, 2003, pp 224-246